TVTX

53.38

0.78% -0.42

Pre-mercato: 53.35 -0.03 -0.06%

Travere Therapeutics Inc (TVTX)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché TVTX Giù? Forum Previsione Frazionamento azionario

Precedente Chiudi:

$53.80

Aprire:

$53.88

Volume 24 ore:

2.19M

Relative Volume:

0.98

Capitalizzazione di mercato:

$4.96B

Reddito:

$536.20M

Utile/perdita netta:

$-45.64M

Rapporto P/E:

-99.81

EPS:

-0.5348

Flusso di cassa netto:

$-28.94M

1 W Prestazione:

+9.90%

1M Prestazione:

+25.33%

6M Prestazione:

+48.90%

1 anno Prestazione:

+263.62%

Intervallo 1D:

$52.72

$54.38

Intervallo di 1 settimana:

$46.54

$54.38

Portata 52W:

$13.88

$54.38

Travere Therapeutics Inc Stock (TVTX) Company Profile

Nome

Travere Therapeutics Inc

Settore

Healthcare (1107)

Industria

Biotechnology (621)

Telefono

888-969-7879

Indirizzo

3611 VALLEY CENTRE DR, SAN DIEGO

Dipendente

497

Cinguettio

Prossima data di guadagno

2026-08-05

Ultimi documenti SEC

TVTX's Discussions on Twitter

Compare TVTX vs VRTX, REGN, ARGX, ALNY, RVMD

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
TVTX Travere Therapeutics Inc	53.38	5.00B	536.20M	-45.64M	-28.94M	-0.5348
VRTX Vertex Pharmaceuticals Inc	453.17	114.33B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	614.73	64.47B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	878.49	54.99B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	281.90	38.42B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	156.58	34.03B	742.00K	-1.37B	-1.07B	-7.0731

Travere Therapeutics Inc Stock (TVTX) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2026-04-14	Aggiornamento	Piper Sandler	Neutral → Overweight
2025-10-31	Reiterato	Citigroup	Buy
2025-06-11	Reiterato	Citigroup	Buy
2025-06-11	Ripresa	H.C. Wainwright	Buy
2025-01-10	Iniziato	Cantor Fitzgerald	Overweight
2024-10-21	Aggiornamento	Wells Fargo	Equal Weight → Overweight
2024-10-16	Iniziato	Scotiabank	Sector Outperform
2024-09-09	Aggiornamento	Guggenheim	Neutral → Buy
2024-03-27	Downgrade	Guggenheim	Buy → Neutral
2023-12-05	Aggiornamento	Citigroup	Neutral → Buy
2023-11-20	Iniziato	Citigroup	Neutral
2023-09-22	Downgrade	Wells Fargo	Overweight → Equal Weight
2023-09-21	Downgrade	William Blair	Outperform → Mkt Perform
2023-09-06	Ripresa	Evercore ISI	Outperform
2023-07-21	Iniziato	JP Morgan	Overweight
2023-06-07	Ripresa	Piper Sandler	Neutral
2023-05-22	Iniziato	TD Cowen	Outperform
2023-05-05	Aggiornamento	Bryan Garnier	Sell → Neutral
2023-03-01	Iniziato	Guggenheim	Buy
2023-02-21	Aggiornamento	Wedbush	Neutral → Outperform
2022-12-14	Iniziato	Stifel	Hold
2022-12-05	Iniziato	Wells Fargo	Overweight
2022-09-21	Iniziato	Bryan Garnier	Sell
2022-07-14	Ripresa	Canaccord Genuity	Buy
2022-03-31	Iniziato	Piper Sandler	Overweight
2022-02-28	Iniziato	H.C. Wainwright	Buy
2021-05-26	Downgrade	Wedbush	Outperform → Neutral

Mostra tutto

Travere Therapeutics Inc Borsa (TVTX) Ultime notizie

Jun 15, 2026

TVTX Maintained by Citigroup -- Price Target Raised to $70.00 - GuruFocus

Jun 15, 2026

Travere Therapeutics price target raised to $70 from $62 at Citi - TipRanks

Jun 15, 2026

TVTX Stock On Track To Hit Near 20-Year Highs After Filspari Becomes The Only Approved FSGS Treatment - Stocktwits

Jun 15, 2026

Jun 13, 2026

TVTX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI

Jun 13, 2026

Is Travere Therapeutics, Inc. (TVTX) A Good Stock To Buy Now? - Insider Monkey

Jun 13, 2026

TVTX, LGND Stocks In Spotlight Ahead Of Monday’s FDA Call On Kidney Drug Filspari - Stocktwits

Jun 13, 2026

TVTX Maintains Overweight Rating by Wells Fargo -- Price Target Raised to $65 - GuruFocus

Jun 13, 2026

Jun 12, 2026

Travere Stock At 20-Year High, Leads 21 Newcomers To Best Stock Lists Like Big Cap 20 - Investor's Business Daily

Jun 11, 2026

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Enidnews.com

Jun 11, 2026

Travere Therapeutics Wins Much-Awaited Approval For Drug In Rare Kidney Disease - Stocktwits

Jun 11, 2026

Jun 10, 2026

Travere Therapeutics stock hits 52-week high at 48.7 USD By Investing.com - Investing.com Australia

Jun 10, 2026

Jun 09, 2026

Travere Therapeutics stock hits 52-week high at 48.7 USD - Investing.com

Jun 09, 2026

Jun 08, 2026

3 Stocks That May Be Priced Below Their Estimated Value In June 2026 - simplywall.st

Jun 08, 2026

Travere Therapeutics Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus

Jun 08, 2026

Jun 07, 2026

Discipline and Rules-Based Execution in TVTX Response - Stock Traders Daily

Jun 07, 2026

Jun 06, 2026

Travere therapeutics CCO sells $101,417 in stock for tax obligations - Investing.com

Jun 06, 2026

Jun 05, 2026

Travere therapeutics chief research officer Rote sells $121,433 in shares - Investing.com

Jun 05, 2026

Travere inks licensing deal worth up to $1.1B with China’s Everest Medicines - MSN

Jun 05, 2026

Travere buys BTK inhibitor for $1.1bn to treat kidney disease - BioXconomy

Jun 05, 2026

Everest Medicines Enters into Exclusive Licensing Agreement with Travere Therapeutics for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases, Driving Value Conversion - ANTARA News

Jun 05, 2026

Jun 04, 2026

Travere Secures Global Rights to Civorebrutinib in $1.14 Billion Kidney Disease Partnership with Everest Medicines - BioPharma APAC

Jun 04, 2026

Travere Therapeutics (TVTX) Rises 2.72% as Stock Nears Key Resistance LevelAdaptive Moving Average - newsline.com

Jun 04, 2026